Meeting
2020 ASCO Virtual Scientific Program
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
Authors
Georgina V. Long
Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
Georgina V. Long , Celeste Lebbe , Victoria Atkinson , Mario Mandalà , Paul D. Nathan , Ana Arance , Erika Richtig , Naoya Yamazaki , Caroline Robert , Dirk Schadendorf , Hussein Abdul-Hassan Tawbi , Paolo Antonio Ascierto , Antoni Ribas , Keith Flaherty , Neha Pakhle , Aisha Masood , Eduard Gasal , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02967692
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10028)
DOI
10.1200/JCO.2020.38.15_suppl.10028
Abstract #
10028
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
First Author: Reinhard Dummer
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
First Author: Georgina V. Long
Poster
2023 ASCO Annual Meeting
Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.
First Author: Jun Guo